Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why IBM's Leading the Dow Downward This Morning

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The stock market has definitely taken investors on a roller-coaster ride over the past few weeks, as uncertainties about the basic fundamental health of the economy and the role of central banks in stabilizing and fostering economic growth continue to linger. With various officials at the Federal Reserve taking slightly different positions in interpreting the central bank's recent actions and statements, investors have gotten whipsawed, and today, fears of a near-term reduction in the amount of bond-buying the Fed will do in the near future helped send stocks down. As of 10:45 a.m. EDT, the Dow Jones Industrials (DJINDICES: ^DJI  ) were down 92 points after having fallen triple-digits earlier in the morning.

The Dow suffered greater losses than the overall market largely because of the influence of IBM (NYSE: IBM  ) , which fell 2.6%. Rival Accenture (NYSE: ACN  ) , which is the major competitor against IBM in the lucrative information-technology consulting business, gave reduced guidance for full-year results when it reported earnings last night. Pointing to weakness in its consulting business, Accenture cut the midpoint of its earnings forecast range by about 2% and pushed down its expected range for revenue growth to just 3% to 4%. Accenture fell 13% on the news, but investors concluded that prospects for the entire industry were weak and therefore bid IBM down in sympathy. Since IBM's share price is by far the largest in the Dow, the loss had a big overall impact on the entire average.

Merck (NYSE: MRK  ) and Johnson & Johnson (NYSE: JNJ  ) also declined in early trade, with Merck down about 1% and J&J falling three-quarters of a percent on news that two biosimilar versions of the two companies' Remicade rheumatoid arthritis drug had gained recommendations from experts at the European Medicines Agency. Biosimilars have the potential to pose an equal threat to Remicade and other biologic treatments that generics have on traditional pharmaceuticals, but the biosimilar versions could still face challenges in getting widespread adoption. With both companies having rights to market the drug in various regions of the world, Merck and J&J both have an interest in keeping biosimilars out of the market.

Finally, outside the Dow, gold prices once again fell, dropping below the $1,200 per ounce level. Yet once again, gold-mining stocks rose, with the Market Vectors Gold Miners ETF rising nearly 5%. This disconnect isn't sustainable, but it shows the extent to which mining stocks got sold off -- to an even greater extent than bullion during gold's pullback over the past couple of years.

If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.

Read/Post Comments (1) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 28, 2013, at 1:02 PM, shegde wrote:

    re: IBM, I also welcome feedback/comments about the recent announcements from rival, ORCL on partnering with MSFT,CRM and the likes in their hardware segments ... shouldn't that materially impact IBM?

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2515319, ~/Articles/ArticleHandler.aspx, 9/26/2016 8:29:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:35 PM
^DJI $18094.83 Down -166.62 -0.91%
ACN $113.73 Up +0.64 +0.57%
Accenture CAPS Rating: ****
IBM $153.98 Down -1.00 -0.65%
IBM CAPS Rating: ****
JNJ $117.78 Down -1.03 -0.87%
Johnson and Johnso… CAPS Rating: *****
MRK $62.15 Down -0.81 -1.29%
Merck and Co. CAPS Rating: ****